Skip to main content
. 2023 Jan 24;14:1117448. doi: 10.3389/fimmu.2023.1117448

Figure 5.

Figure 5

Forest plots of efficacy and safety in ESCC. (A) Pathological complete response (pCR), (B) Major pathological response (MPR), (C) R0 resection rate, (D) Incidence of ≥grade 3 TRAEs, (E) Neoadjuvant therapy completion rate, (F) surgical resection rate, and (G) Surgical delay rate. NICRT, neoadjuvant immune-chemoradiotherapy; NICT, neoadjuvant immune-chemotherapy.